Having trouble viewing this email? View in your browser.
Header
 
 
WELCOME
 
Dear Colleague,
 
It is with great pleasure that we welcome you to the 32nd ECCMID Congress and invite you to join us for the Gilead integrated symposium:
 
Optimising treatment of invasive fungal infections in critically ill patients
 
We will explore issues encountered by healthcare professionals when managing invasive fungal infections in critically ill patients, including discussion of diagnostic challenges and capabilities around the globe, and the optimal management of antifungal-related safety considerations.
 
We hope you will join us for what promises to be an engaging and thought-provoking symposium.
 
 
 
SectionHeader
 
munoz
 
Professor
Patricia Muñoz (Spain)
 
SectionHeader
 
calandra
 
Professor
Thierry Calandra
(Switzerland)
 
 
SectionHeader
 
cornelia
 
Professor
Martin Hoenigl
(Austria)
cornelia
 
Professor
Cornelia Lass-Flörl
(Austria)
 
lewis
 
Professor
Russell Lewis
(Italy)
maertens
 
Professor
Johan Maertens
(Belgium)
 
 
 
AGENDA
 
 
 
  TIME (WEST)   TOPIC FACULTY  
 
 
 
13:30   Welcome and Introduction Chair: Professor Patricia Muñoz (Spain) ESCMID-appointed Chair: Thierry Calandra
 
 
 
 
13:40   Diagnostic challenges – capabilities for timely diagnosis of IFI in the ICU & ECMM global survey of diagnostic capacity Martin Hoenigl (Austria)
 
 
 
 
14:00   Spectrum of activity of antifungal treatments & clinical implementation of
MIC distributions		 Cornelia Lass-Flörl (Austria)
 
 
 
 
14:20   Principles for assessing antifungal tissue distribution – fungicidal vs fungistatic attributes of antifungal treatments in deep-seated IFI/ biofilms   Russell Lewis (Italy)
 
 
 
 
14:40   Practical considerations in the management of antifungal treatment – drug-drug interactions and safety profile considerations   Johan Maertens (Belgium)
 
 
 
 
15:00   Q&A   All
 
 
 
 
15:20   Summary/meeting close   Chair/ESCMID-appointed Chair
 
 
 
 
  footer IHQ-AMB-0487
Date of preparation: March 2022		  
 
 
This medical educational symposium is initiated and fully funded by Gilead Sciences Europe Ltd.
Due to host country regulations, some of the content is considered promotional.
For healthcare professionals only
 
You have received this email as a contact of ESCMID or one of its affiliated societies.
You can unsubscribe here.